Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CLIC-2201 |
| Synonyms | |
| Therapy Description |
CLIC-2201 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CD22, which potentially induce killing of tumor cells expressing CD22 (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CLIC-2201 | CLIC 2201|CLIC2201 | CD22 Immune Cell Therapy 13 | CLIC-2201 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CD22, which potentially induce killing of tumor cells expressing CD22 (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06208735 | Phase I | CLIC-2201 | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies | Recruiting | CAN | 0 |